Luzitin attends the BIO-Europe Spring® conference, in France

2015-02-19 in Press Release Luzitin

From March 9th to 11th, Luzitin takes a unique opportunity for partnering and seeks to out-license its innovative technology in cancer response.

Luzitin, S.A. will attend the largest springtime life science partnering conference in Europe. This year, BIO-Europe Spring® takes place in Paris, from March 9th to 11th.

Sérgio Simões integrates the speakers’ panel about oncology on the 10th march, by 12h30. The Luzitin’s executive chairman will provide updates on the promising clinical results obtained in the advanced Head&Neck cancer response using the lead compound, LUZ11.

These clinical findings clearly reinforce the favourable PK properties, convenience of use, safety profile and efficacy previously demonstrated in non-clinical studies. Luzitin will be looking for partnerships in order to further proceed on the clinical development of its technology.

This participation is encompassed in the scope of the Biocant International Project and funded by the incentives system to the SMEs Qualification and Internationalization.

 

About BIO-Europe Spring®

The event is the meeting point for start-ups and big biotech companies desiring to form business partnerships with investors and big pharma companies. In 2014, more than 2,000 attendees from 1,209 companies participated in 10,780 one-to-one meetings, involving 2,115 licensing opportunities.



Bluepharma
Bluepharma
Bluepharma
Bluepharma
Bluepharma
Bluepharma